Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients by unknown
ORIGINAL ARTICLE
Combination of platelet count and mean platelet volume
(COP-MPV) predicts postoperative prognosis in both resectable
early and advanced stage esophageal squamous
cell cancer patients
Fan Zhang1 & Zhaoli Chen1 & Pan Wang1 & Xueda Hu1 & Yibo Gao1 & Jie He1
Received: 4 November 2015 /Accepted: 29 December 2015 /Published online: 16 January 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The aim of this study is to search the most powerful
prognostic factor from routine blood test for esophageal squa-
mous cell cancer (ESCC) patients. Multiple laboratory tests
were evaluated including those reflecting red blood cell pa-
rameters (hemoglobin (Hb), mean corpuscular volume
(MCV), mean corpuscular hemoglobin concentration
(MCHC), and red blood cell distributionwidth (RDW)), plate-
let morphological parameters (mean platelet volume (MPV)
and platelet count (PLT)), blood coagulation status (D-dimer),
and tumor biomarker (CA19-9). Known inflammatory indices
(NLR and PLR) were also calculated. A total of 468 patients
who were diagnosed with ESCC between December 2005 and
December 2008 were retrospectively analyzed in this study.
By utilizing univariate and multivariate Cox proportional haz-
ard analyses, we found that PLT and MPV were significantly
associated with overall survival (OS) and disease-free survival
(DFS) of ESCC patients, with optimal cutoff values of 212
and 10.6, respectively. Moreover, the combination of the pre-
operative PLT and MPV (COP-MPV) was calculated as fol-
lows: patients with both PLT (≥212 × 109 L−1) and MPV
(≥10.6 fL) elevation were assigned a score of 2, and patients
with one or neither were assigned a score of 1 and 0. The
COP-MPVwas an independent prognostic factor for OS (haz-
ard ratio (HR) 0.378, 95 % confidence interval (CI) 0.241 to
0.593, P<0.001, 0/2) and DFS (HR 0.341, 95 % CI 0.218 to
0.534, P<0.001, 0/2) in multivariate analyses. In subgroup
analyses for early (stages I and II) and locally (stage III)
advanced stage patients, COP-MPV was found significantly
associated with OS and DFS in each group (P=0.025 and
P=0.018 for OS and P=0.029 and P=0.002 for DFS). In
conclusion, we considered that COP-MPV is a promising pre-
dictor for postoperative survival in ESCC patients.
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Introduction
Among the most lethal malignancies, esophageal cancer (EC)
ranks the sixth worldwide, leading to approximately 400,000
deaths in 2012 [1]. In China, esophageal cancer is the fourth
leading cause of all cancer deaths, representing a major prob-
lem of public health in some high-risk rural areas [2]. The
dominant histopathological type of EC is squamous cell car-
cinoma (ESCC) in Chinese patients, which covers 90 % of all
cases [3]. Despite the progress in radical resection and adjuvant
therapy (radiation and chemotherapy), ESCC still shows a poor
5-year survival rate of less than 30 % [4]. The tumor node
metastasis (TNM) staging, especially the status of lymph node
metastasis, is currently the best predictor for ESCC patient sur-
vival [5]. Although several studies had identified certain survival-
related biomarkers [6–8], theywere less powerful and hardly able
to be converted to clinical use. Thus, it is important to recognize
effective and easy-obtained biomarkers for ESCC prognosis.
In the past decade, platelet activation has been demonstrat-
ed as a crucial biological process in carcinogenesis and me-
tastasis [9–11]. Platelet count (PLT) and mean platelet volume
(MPV) are two main characteristics to evaluate platelet acti-
vation [12]. Patients with thrombocytosis have been reported
to have worse prognosis in multiple solid tumors, such as
ovarian cancer [13], endometrial cancer [14], gastric cancer
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[15], and colorectal cancer [16]. On the other hand, highMPV
reflected an abnormal rate of platelet production and stimula-
tion [17]. Recent studies revealed that MPV levels were rela-
tively higher in tumor patients than in normal controls and
associated with poor prognosis in some gastrointestinal neo-
plasms [18–20]. However, the predictive value of PLT com-
bined with MPV for postsurgery survival in ESCC has not
been yet investigated.
In this study, we assessed and checked the prognostic value
of preoperative PLT and MPV in 468 ESCC patients. More-
over, we took the utility of a novel prognostic system based on
platelet activation, termed combination of platelet count and
MPV (COP-MPV), which made a promising distinction be-
tween better and worse prognosis in both subgroups of early




Patients with histopathologically confirmed ESCC with no
distal metastasis (TNM stage I–III) were enrolled in the study
from December 2005 to December 2008. All patients
underwent esophagectomy at the Cancer Institute and Hospi-
tal, Chinese Academy of Medical Sciences (CAMS), with
written informed consent. The exclusion criteria were (1) se-
vere complications or deaths occurred within 30 days after
surgery, (2) preoperative systemic inflammatory response syn-
drome (SIRS), (3) neoadjuvant radiotherapy or chemotherapy,
and (4) evidence of infection or autoimmune disease. All pa-
tients underwent a careful preoperative evaluation, including
clinical history taking, physical examination, laboratory blood
testing (biochemistry, complete blood cell counts, coagulation
status, and serum tumor marker), pulmonary function test, and
multiple radiography (computed tomography (CT) or magnet-
ic resonance imaging (MRI)). Clinicopathological informa-
tion of the patients were obtained from the medical records,
including age, gender, smoking history, drinking status, tumor
location, differentiation grade, maximum tumor diameter,
lymph node metastasis, TNM stage, and history of adjuvant
chemotherapy and radiotherapy. The TNM stage was assessed
according to American Joint Committee on Cancer (AJCC)
staging manual (seventh edition) [21]. Patients underwent ad-
juvant radio/chemotherapy after surgery according to TNM
stages and family economic status. The laboratory character-
istics, including hemoglobin (Hb), mean corpuscular volume
(MCV), mean corpuscular hemoglobin concentration
(MCHC), red blood cell distribution width (RDW), mean
platelet volume (MPV), platelet count (PLT), D-dimer, and
CA19-9, were performed within 5 days prior to surgery. The
last follow-up date was July 9, 2015. This study was approved
by the medical ethics committee of the Cancer Institute and
Hospital, CAMS.
Statistical analysis
Overall survival (OS) was defined as follows: the time from
surgery to the time of patients’ death for any cause or the last
follow-up date when the patient was known alive. Disease-
free survival (DFS) was calculated from the date of operation
to first tumor recurrence. Neutrophil-lymphocyte ratio (NLR)/
platelet-lymphocyte ratio (PLR) was, respectively, defined as
absolute neutrophil/lymphocyte count divided by absolute
lymphocyte count. Categorical variables were shown as fre-
quency (percentage), while continuous variables were pre-
sented as the mean values± standard deviation. Unpaired t or
χ2 test was used to compare whether statistical differences
between groups were significant. The optimal cutoff values
of all continuous variables were determined by receiver oper-
ating characteristic (ROC) curve. We used univariate analysis
to narrow down the list of possible prognostic factors. Vari-
ables with P value<0.1 in univariate analysis were brought
into multivariate Cox proportional hazard model to determine
their independency. Specifically, the cutoff values of PLT and
MPV were 212 (×109 L−1) and 10.6 (fL), respectively. The
COP-MPV score was calculated on the basis of these two
platelet characteristics. Patients with both a higher platelet
count (≥212×109 L−1) level and a higher mean platelet vol-
ume (≥10.6 fL) level were grouped a score of 2, and patients
with one or neither were grouped a score of 1 and 0, respec-
tively. Kaplan-Meier curves and log-rank test were used to
compare survival differences among groups. All statistical
analyses were conducted by SPSS 21.0 software (IBM Cor-
poration, Somers, NY, USA). P<0.05 was considered statis-
tically significant.
Results
A total of 468 patients were enrolled in this study, including
376 men and 92 women. The mean age of all patients was
59.5±9.0 years (median age 60 years; range 36 to 81). Mean
follow-up period was 49.1 ± 32.6 months (range 3.2 to
114.5 months). Two-hundred seventy (57.7 %) patients had
died during the observation period. The 5-year overall surviv-
al rate was 45.0 % for the whole cohort. The distribution of
TNM stages was stage I, 46 (9.8 %); stage II, 199 (42.6 %);
and stage III, 223 (47.6 %). Mean PLT and MPV were 218
±65×109 L−1 (range 52 to 611) and 10.6±1.1 fL (range 7.1 to
14.4), respectively. Mean (SD, range) levels of other selected
laboratory variables or ratios were as follows: Hb, 145 gL−1
(15, 65 to 194); MCV, 94.4 fL (5.1, 76.7 to 114.4); MCHC,
342 gL−1 (11, 311 to 378); RDW, 12.8 % (0.8, 10.4 to 16.5);
D-dimer, 155 μg L−1 (129, 18 to 1522); CA19-9,
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Table 1 Clinical characteristics
between different COP-MPV
groups








<60 35 (41.2) 160 (50.6) 32 (47.8)
≥60 50 (58.8) 156 (49.4) 35 (52.2)
Sex 0.004
Female 20 (23.5) 50 (15.8) 22 (32.8)
Male 65 (76.5) 266 (84.2) 45 (67.2)
Smoking 0.034
Ever 57 (67.1) 163 (51.6) 39 (58.2)
Never 28 (32.9) 153 (48.4) 28 (41.8)
Drinking 0.157
Yes 36 (42.4) 114 (36.1) 32 (47.8)
No 49 (57.6) 202 (63.9) 35 (52.2)
Tumor location <0.001
Upper 16 (18.8) 187 (59.2) 13 (19.4)
Middle + lower 69 (81.2) 129 (40.8) 54 (80.6)
Differentiation 0.916
High 20 (23.5) 84 (26.6) 17 (25.4)
Moderate 41 (48.2) 157 (49.7) 32 (47.8)




≥7.0 18 (21.2) 73 (23.1) 15 (22.4)
<7.0 67 (78.8) 243 (76.9) 52 (77.6)
N metastasis 0.508
Yes 37 (43.5) 160 (50.6) 33 (49.3)
No 48 (56.5) 156 (49.4) 34 (50.7)
TNM stage 0.096
I 14 (16.5) 28 (8.9) 4 (6.0)
II 39 (45.9) 133 (42.1) 27 (40.3)
III 32 (37.6) 155 (49.1) 36 (53.7)
Adjuvant radio/chemotherapy 0.484
Yes 42 (49.4) 160 (50.6) 39 (58.2)
No 43 (50.6) 156 (49.4) 28 (41.8)




Variables COP-MPV=0 (n =75) COP-MPV= 1 (n= 316) COP-MPV= 2 (n= 67) P value
Hb (gL−1) 144.0 ± 16.3 145.2 ± 14.7 144.1 ± 14.7 0.728
MCV (fL) 94.3 ± 5.2 94.6 ± 5.2 93.3 ± 4.6 0.149
MCHC (gL−1) 343.1 ± 10.1 342.8 ± 11.3 339.4 ± 11.5 0.064
RDW (%) 12.7 ± 0.8 12.8 ± 0.7 12.9 ± 0.7 0.203
MPV (fL) 9.8 ± 0.6 10.6 ± 1.1 11.3 ± 0.5 <0.001
PLT (×109 L−1) 174.6 ± 28.2 221.9 ± 70.3 254.4 ± 32.9 <0.001
D-dimer (μg L−1) 186.3 ± 201.4 142.0 ± 99.1 175.9 ± 129.6 0.007
CA19-9 (U mL−1) 10.7 ± 6.9 12.2 ± 16.2 10.2 ± 6.2 0.916
NLR 1.9 ± 1.0 2.0 ± 1.0 1.9 ± 1.4 0.517
PLR 97.0 ± 30.0 111.7 ± 43.4 116.3 ± 32.4 0.004
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11.63 U mL−1 (13.83, 0.35 to 145.30); NLR, 1.98 (1.02, 0.53
to 11.00); and PLR, 109.66 (40.20, 32.79 to 418.52).
The relationship between COP-MPV and clinical char-
acteristics of patients with ESCC was shown in Table 1.
Most indices had no significant differences among three
groups except for sex (P = 0.004), smoking history
(P=0.034), tumor location (P<0.001), and survival period
(P<0.001).
Table 3 Univariate analyses of
overall survival and disease-free
survival for all ESCC patients
Variables P value OS HR (95 % CI) P value DFS HR (95 % CI)
Age (≥60 vs <60) 0.001 1.537 0.002 1.459
(1.206 to 1.959) (1.145 to 1.860)
Sex (male vs female) 0.591 1.088 0.496 1.113
0.800 to 1.479 0.818 to 1.513
Tumor location (upper vs middle + lower) 0.444 1.143 0.388 1.163
(0.811 to 1.611) (0.825 to 1.639)
Differentiation (high, moderate, and poor) 0.910 1.019 0.952 1.010
(0.738 to 1.407) (0.732 to 1.395)
N metastasis (presence vs absence) <0.001 2.134 <0.001 2.116
(1.671 to 2.726) (1.657 to 2.702)
TNM stage (I + II vs III) <0.001 0.434 <0.001 0.433
(0.340 to 0.554) (0.339 to 0.553)
Adjuvant radio/chemotherapy (yes vs no) <0.001 1.749 <0.001 1.846
(1.370 to 2.234) (1.445 to 2.358)
Smoking (ever vs never) 0.033 1.297 0.025 1.313
(1.021 to 1.647) (1.034 to 1.667)
Drinking (yes vs no) 0.576 1.073 0.601 1.068
(0.839 to 1.372) (0.835 to 1.366)
Maximum tumor diameter (≥7.0 vs <7.0 cm) 0.001 1.580 0.001 1.599
(1.206 to 2.070) (1.220 to 2.095)
Hb (≥135 vs <135 gL−1) 0.228 0.847 0.251 0.854
(0.647 to 1.109) (0.652 to 1.118)
MCV (≥98.7 vs <98.7 fL) 0.070 1.329 0.071 1.327
(0.977 to 1.808) (0.976 to 1.806)
MCHC (≥344 vs <344 gL−1) 0.755 1.039 0.660 1.055
(0.817 to 1.321) (0.830 to 1.342)
RDW (≥12.2 vs <12.2 %) 0.020 1.505 0.027 1.474
(1.068 to 2.122) (1.046 to 2.077)
MPV (≥10.6 vs <10.6 fL) 0.013 1.354 0.015 1.347
(1.066 to 1.720) (1.060 to 1.710)
PLT (≥212 vs <212 × 109 L−1) 0.019 1.332 0.003 1.431
(1.048 to 1.692) (1.127 to 1.819)
D-dimer (≥207 vs <207 μg L−1) 0.164 1.215 0.231 1.182
(0.924 to 1.597) (0.899 to 1.554)
CA19-9 (≥4.79 vs <4.79 U mL−1) 0.005 1.561 0.005 1.559
(1.148 to 2.123) (1.147 to 2.120)
NLR (≥2.50 vs <2.50) 0.019 1.417 0.024 1.400
(1.058 to 1.899) (1.045 to 1.875)
PLR (≥117.07 vs <117.07) 0.047 1.288 0.039 1.301
(1.003 to 1.653) (1.014 to 1.670)
COP-MPV (0, 1, and 2) <0.001 0.394 (0–2) <0.001 0.350 (0–2)
(0.254 to 0.611) (0.226 to 0.543)
0.691 (1–2) 0.630 (1–2)
(0.504 to 0.948) (0.459 to 0.863)
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Table 2 showed the distribution of multiple laboratory var-
iables in three groups divided by COP-MPV. MPV
(P<0.001), PLT (P<0.001), D-dimer (P=0.007), and PLR
(P=0.004) showed significant differences.
We next separated the cohort into different groups by cutoff
values of clinicolaboratory variables. Survival analyses of OS
and DFS in relation to every selected variable were performed.
In univariate analyses, age (≥60/<60) (hazard ratio (HR)
1.537, 95 % confidence interval (CI) 1.206 to 1.959,
P=0.001), lymph node metastasis (presence/absence) (HR
2.134, 95 % CI 1.671 to 2.726, P<0.001), TNM stage (I +
II/III) (HR 0.434, 95%CI 0.340 to 0.554,P<0.001), adjuvant
therapy (yes/no) (HR 1.749, 95 % CI 1.370 to 1.224,
P<0.001), smoking (ever/never) (HR 1.297, 95 % CI 1.021
to 1.647, P = 0.033), maximum tumor diameter (≥7.0/
<7.0 cm) (HR 1.580, 95 % CI 1.206 to 2.070, P=0.001),
RDW (≥12.2/<12.2 %) (HR 1.505, 95 % CI 1.068 to 2.122,
P=0.020), MPV (≥10.6/<10.6 fL) (HR 1.354, 95 % CI 1.066
to 1.720, P=0.013), PLT (≥212/<212×109 L−1) (HR 1.332,
95 % CI 1.048 to 1.692, P = 0.019), CA19-9 (≥4.79/
<4.79 U mL−1) (HR 1.561, 95 % CI 1.148 to 2.123,
P=0.005), NLR (≥2.50/<2.50) (HR 1.417, 95 % CI 1.058 to
1.899, P=0.019), PLR (≥117.07/<117.07) (HR 1.288, 95 %
CI 1.003 to 1.653, P=0.047), and COP-MPV (HR 0.394,
95 % CI 0.254 to 0.611, P<0.001) were associated with OS
(Table 3). Similar results were revealed in the relationships of
these factors with DFS (Table 3). Multivariate analyses dem-
onstrated that age (HR 1.595, 95 % CI 1.236 to 2.059,
P < 0.001), lymph node metastasis (HR 1.869, 95 % CI
1.421 to 2.458, P < 0.001), adjuvant therapy (HR 1.327,
95% CI 1.006 to 1.751, P=0.045), maximum tumor diameter
(HR 1.365, 95 % CI 1.019 to 1.828, P=0.037), CA19-9 (HR
1.740, 95 % CI 1.270 to 2.385, P<0.001), and COP-MPV
(HR 0.378, 95 % CI 1.270 to 2.385, P<0.001) were indepen-
dent prognostic factors of ESCC patients (Table 4).
Moreover, we examined the prognostic value of COP-
MPV in subgroups of early and advanced stages of ESCC
patients. Hazard ratios of OS and DFS were found significant-
ly different among three COP-MPV groups in both early (OS,
P = 0.025; DFS, P = 0.018) and advanced stages (OS,
P=0.029; DFS, P=0.002). However, PLT or MPValone did
not show that predictive function as they combined (MPV for
early stage, P=0.334 (Fig. 2a); MPV for advanced stage,
P=0.085 (Fig. 2b); and PLT for advanced stage, P=0.254
(Fig. 3b)) (Table 5).
By Kaplan-Meier analyses, significant differences in OS
and DFS among COP-MPV groups were demonstrated
(P<0.001), where COP-MPV=2 group tended to have worse
Table 4 Multivariate analyses
of overall survival and
disease-free survival for all
ESCC patients
Variables P value OS HR (95 % CI) P value DFS HR (95 % CI)
Age (≥60 vs <60) <0.001 1.595 0.002 1.498
(1.236 to 2.059) (1.162 to 1.930)
N metastasis (yes vs no) <0.001 1.869 <0.001 1.816
(1.421 to 2.458) (1.381 to 2.389)
Adjuvant radio/chemotherapy (yes vs no) 0.045 1.327 0.015 1.411
(1.006 to 1.751) (1.070 to 1.860)
Smoking (ever vs never) 0.622 1.066 0.611 1.068
(0.827 to 1.374) (0.830 to 1.373)
Maximum tumor diameter (≥7.0 vs <7.0 cm) 0.037 1.365 0.046 1.348
(1.019 to 1.828) (1.006 to 1.806)
MCV (≥98.7 vs <98.7 fL) 0.095 1.310 0.092 1.311
(0.954 to 1.798) (0.957 to 1.796)
RDW (≥12.2 vs <12.2 %) 0.095 1.356 0.101 1.349
(0.948 to 1.940) (0.943 to 1.929)
CA19-9 (≥4.79 vs <4.79 U mL−1) 0.001 1.740 0.001 1.722
(1.270 to 2.385) (1.258 to 2.358)
NLR 0.124 1.283 0.180 1.245
(0.934 to 1.763) (0.904 to 1.714)
PLR 0.187 1.203 0.172 1.210
(0.915 to 1.582) (0.920 to 1.591)
COP-MPV (0, 1, and 2) <0.001 0.378 (0–2) <0.001 0.341 (0–2)
(0.241 to 0.593) (0.218 to 0.534)
0.677 (1–2) 0.620 (1–2)
(0.490 to 0.535) (0.449 to 0.856)
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prognosis than other two groups (Fig. 1a, b). The 5-year sur-
vival rates for groups 0, 1, and 2 were 64.3, 43.1, and 28.0 %,
respectively.We illustrated the effect of one known prognostic
factor (lymph node metastasis) to postoperative survival for


























































































Fig. 1 Kaplan-Meier curves of
overall survival (a) and disease-
free survival (b) for 468 ESCC
patients by COP-MPV category.
P values were determined by the
log-rank test. Relationship
between known prognostic
factors (lymph node metastasis
status) and OS/DFS were shown
in (c) and (d) for comparison
Table 5 Univariate analyses of
overall survival and disease-free
survival for early stage (TNM I
and II) and locally advanced
(TNM III) stage patients
Variables TNM
stage
P value OS HR (95 % CI) P value DFS HR (95 % CI)
MPV (≥10.6 vs <10.6 fL) I and II 0.334 1.203 0.349 1.196
(0.827 to 1.752) (0.822 to 1.742)
III 0.085 1.317 0.098 1.303
(0.963 to 1.801) (0.952 to 1.782)
PLT (≥212 vs <212 × 109 L−1) I and II 0.024 1.545 0.014 1.602
(1.059 to 2.254) (1.099 to 2.337)
III 0.254 1.198 0.050 1.365
(0.878 to 1.634) (1.000 to 1.862)
COP-MPV (0, 1, and 2) I and II 0.025 0.400 (0–2) 0.018 0.385 (0–2)
(0.204 to 0.786) (0.196 to 0.756)
0.732 (1–2) 0.727 (1–2)
(0.438 to 1.225) (0.435 to 1.215)
III 0.029 0.465 (0–2) 0.002 0.371 (0–2)
(0.259 to 0.833) (0.207 to 0.665)
0.671 (1–2) 0.554 (1–2)
(0.450 to 1.001) (0.371 to 0.829)
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comparison (Fig. 1c, d). In subgroup analyses, COP-MPV
showed its predictive value in both early (TNM stages I and
II) and advanced stages (TNM stage III) of ESCC patients. In
the early stage subgroup, patients with COP-MPV=2 were
prone to live shorter compared to 0 or 1 groups (P=0.025)
(Fig. 2c), where 5-year survival rates for groups 0, 1, and 2
were 74.5, 55.2, and 44.1 %, respectively. Similar results were
revealed in the advanced stage group (P=0.029; Fig. 3c),
where 5-year survival rates for groups 0, 1, and 2 were 46.9,
31.3, and 16.7 %, respectively.
Discussion
Platelet activation has been previously reported as a common
phenomenon in cardiovascular diseases such as acute ische-
mic stroke, myocardial infarction, and renal artery stenosis
[22, 23]. Recently, more attention has been paid on the clinical
significance of this process in several malignancies [24, 25].
The two main aspects to assess the platelet activation status
are PLTandMPV [12]. Researchers noticed that many cancers
were related to elevation of platelet count in peripheral blood
(or thrombocytosis), which were considered to be caused by
upstream cytokine stimulation [26] or oncogenesis itself [27,
28]. Emerging evidence suggested that high PLT or PLR in-
dicated poor postoperative survival in several solid tumors
[13, 29–31]. On the other hand, MPValso showed promising
utility to stratify benign and malignant diseases, although high
MPV indicated that malignant disease/poor survival remained
controversial [32–34]. Therefore, it is reasonable to combine
PLT and MPV as a scoring system (COP-MPV) for platelet
activation to evaluate the prognosis of cancer patients.
In this study, we evaluated the association between multi-
ple clinicopathological variables and OS/DFS and found that
COP-MPV had the best discriminatory ability as lymph node
metastasis status (Table 4 and Fig. 1). NLR and PLRwere also
significant prognostic factors in univariate analysis but not
independent in multivariate Cox regression. This was possibly
because their stratifying ability was absorbed by the COP-






























































Fig. 3 Kaplan-Meier curves of overall survival for stage III patients (n = 223) by aMPV, b PLT, and c COP-MPV categories. P values were determined
by the log-rank test. COP-MPV category showed best predictive power






























































Fig. 2 Kaplan-Meier curves of overall survival for stages I and II patients (n= 245) by a MPV, b PLT, and c COP-MPV categories. P values were
determined by the log-rank test. COP-MPV category showed best predictive power
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MPV score. Moreover, we revealed that COP-MPV had a
predictive utility in both early and advanced subgroups of
ESCC patients (Table 5 and Figs. 2c and 3c). In fact, PLT
was more favorable to stratify the survival period for early
stage ESCC patients (P=0.024; Fig. 2b), while MPV for ad-
vanced stage was though not significant (P=0.085; Fig. 3b).
The combination of PLT and MPV was effective in both sub-
groups as it seemed gathering the advantages of the two indi-
ces measuring platelet activation.
The history for investigating MPV as a tumor prognostic
marker was not long, but evidence was increasing [32,
35–37]. For instance, Aksoy and colleagues demonstrated that
solid tumors with bone marrowmetastasis were more likely to
have low MPV [32]; a Korean group revealed that high MPV
stratified liver cancer compared to normal controls [35]. MPV
level was found significantly higher in advanced endometrial
cancer compared to early stage patients or healthy controls
[36]. Nevertheless, the relationship of MPV value and overall
survival was not consistent in different studies. In non-small-
cell lung cancer (NSCLC), two Japanese groups announced
that low MPV level was associated with unfavorable survival
[34, 37]. Their explanation was that the product for
PLT×MPV was relatively constant. On the other hand, mas-
sive researches proved that high PLT level predicted short
postoperative survival [13–16]. Thus, it was reasonable that
low MPV level (=high PLT level) resembles active inflamma-
tion status which could cause poor prognosis. However, evi-
dence for relationship of highMPVand advanced stage cancer
(or unfavorable disease-like thrombotic state) is also emerg-
ing, such as in colon cancer [38], blood tumor [39], renal
cancer [40], hepatocellular carcinoma [18, 35], gastric cancer
[20], and endometrial cancer [36]. The underlying mechanism
was also straightforward—the process of platelet activation,
stimulated by inflammatory factor such as interleukin-6, was
likely to produce platelet with both characteristics, massive
and giant, not only one. Therefore, we could expect that both
platelet count and volume would be increasing in an unfavor-
able disease compared to a more benign one. Our study in
ESCC supported the latter.
An apparent obstacle for applying these direct blood indi-
ces (such as PLTor MPV) is to determine the cutoff values. In
our study, 41 (8.8 %) patients were with thrombocytosis
(PLT>300×109 L−1) and 9 (1.9 %) patients were with abnor-
mal high MPV (>13.0 fL), which had hardly statistically sig-
nificance on overall survival. However, previous studies on
prognostic potential of these markers revealed that poor sur-
vival was more likely to be related to elevated tendency, not
necessarily to abnormal value (i.e., thrombocytosis or high
MPV) [29, 41]. Actually, indirect indices like PLR or NLR
were widely used partly because the cutoff values for these
indirect indices were not unique. Therefore, our cutoff values
for PLT and MPV based on ROC curves, though not the
normal-abnormal dividing line, were plausible.
In conclusion, our study proved that combined blood bio-
marker COP-MPV has prognostic value in 468 ESCC pa-
tients. Besides, the predictive ability is effective in both early
(TNM I and II) and advanced (TNM III) subgroup patients. To
the best of our knowledge, this is the first time to combine the
two platelet activation markers together to evaluate their prog-
nostic potential, which would help clinicians to predict the
survival of ESCC patients.
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